Jason Inman, PA
Medical · Lansing, MINPI 1265768949
Payments from drug & device makers
Across 493 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Medtronic$1K
- Amgen$1K
- Edwards Lifesciences$1K
- AstraZeneca$862
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$833
- plus $6K from 29 others
What the payments were for
- Travel & lodging$8456%
- Food & beverage$12,62793%
- Education$640%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 42 | $2,321 |
| Medtronic | 36 | $1,266 |
| Amgen | 44 | $1,208 |
| Edwards Lifesciences | 27 | $1,146 |
| AstraZeneca | 23 | $862 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 117 | $833 |
| Shockwave Medical, Inc | 15 | $806 |
| Abbott | 10 | $661 |
| E.r. Squibb & Sons, L.L.C. | 24 | $513 |
| Pfizer | 27 | $509 |
| Boehringer Ingelheim | 20 | $503 |
| Johnson & Johnson | 23 | $446 |
| Novartis | 26 | $444 |
| Teleflex LLC | 6 | $312 |
| Actelion Pharmaceuticals US, Inc. | 11 | $280 |
| Bayer | 13 | $211 |
| Scpharmaceuticals Inc. | 2 | $135 |
| Alnylam Pharmaceuticals Inc. | 4 | $123 |
| Abiomed | 1 | $119 |
| Bridgebio Pharma, Inc. | 2 | $116 |
| Impulse Dynamics (USA) Inc. | 1 | $113 |
| Lilly USA, LLC | 1 | $96 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $91 |
| Philips North America LLC | 1 | $74 |
| Inspire Medical Systems, Inc. | 1 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $53 |
| Angiodynamics, Inc. | 1 | $48 |
| Atricure, Inc. | 1 | $48 |
| Kestra Medical Technology Services, Inc. | 2 | $43 |
| Merck | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Getinge USA Sales, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$965
- SAPIEN 3 Ultra RESILIA$325
- COREVALVE EVOLUT R$313
- MitraClip$286
- Repatha$214
- Micra$154
- PASCAL$145
- MANTA$133
- SHOCKWAVE INTRAVASCULAR LITHOTRIPSY (IVL) SYSTEM WITH THE SHOCKWAVE C2+ CORONARY$130
- HeartMate 3 Left Ventricular Assist Device$127
- Impella$119
- FUROSCIX$115
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$114
- OPTIMIZER SMART SYSTEM$113
- WATCHMAN FLX$111
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$109
- FARXIGA$106
- Watchman$102
- JARDIANCE$101
- Vascular Lithotripsy$101
How this compares
$13,536 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $102,700 |
| EntrestoSacubitril/Valsartan | 38 | $44,800 |
| JardianceEmpagliflozin | 45 | $40,207 |
| Repatha SureclickEvolocumab | 50 | $33,688 |
| XareltoRivaroxaban | 15 | $16,749 |
| BrilintaTicagrelor | 15 | $14,990 |
| Praluent PenAlirocumab | 28 | $14,362 |
| FarxigaDapagliflozin Propanediol | 14 | $13,921 |
| Repatha PushtronexEvolocumab | 11 | $6,512 |
| ClopidogrelClopidogrel Bisulfate | 184 | $3,803 |
| Rosuvastatin Calcium | 72 | $2,388 |
| Metoprolol Succinate | 118 | $2,022 |
| Bumetanide | 45 | $1,875 |
| Ezetimibe | 42 | $1,580 |
| Atorvastatin Calcium | 69 | $1,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $509 | $102,70098 claims |
| NovartisEntresto | $444 | $44,80038 claims |
| Boehringer IngelheimJardiance | $503 | $40,20745 claims |
| AstraZenecaBrilinta, Farxiga | $862 | $28,91229 claims |
| Johnson & JohnsonXarelto | $446 | $16,74915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 755 medical providers in Michigan.
Other medical in Lansing
- Aastyn GuarinoLansing$15K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.